A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

This publication has 23 references indexed in Scilit:

• Matrix metalloproteinases in colorectal cancer: Is it worth talking about?
  Cancer and Metastasis Reviews, 2004
• Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial
  Journal of Clinical Oncology, 2003
• Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18
  European Journal Of Cancer, 2001
• Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
  International Journal of Oncology, 2000
• Matrix Metalloproteinase Inhibitor Drugs
  Emerging Drugs, 1997
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Matrix Metalloproteinases and Their Inhibitors in Tumor Progression^a
  Annals of the New York Academy of Sciences, 1994
• Clinical Importance of Metalloproteinases and Their Inhibitors^a
  Annals of the New York Academy of Sciences, 1994
• Regulation of Matrix Metalloproteinase Activity^a
  Annals of the New York Academy of Sciences, 1994
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
  BMJ, 1991